Anti-laminin (LM) 332-type mucous membrane pemphigoid (MMP) is a rare autoimmune bullous disease and was originally discovered as anti-epiligrin cicatricial pemphigoid. Anti-LM332-type MMP has clinical manifestations similar to those of other types of MMP and can only be distinguished through the detection of circulating autoantibodies against LM332. Our group and others have established a number of immunological methods with varying sensitivity and specificity for detection of anti-LM332 autoantibodies; however, none of the established methods has been widely used for clinical diagnosis. There is currently no unified standard treatment, and it is very difficult to completely cure anti-LM332-type MMP. In addition, an increasing body of evidence suggests that there may be a strong correlation between anti-LM332-type MMP and tumors. In this article, we review the current progression of diagnosis and treatment of anti-LM332-type MMP, as well as the possible correlation between anti-LM332-type MMP and tumors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599625 | PMC |
| http://dx.doi.org/10.3390/biom12101461 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potential contribution of anti-p200 autoantibodies to mucosal lesions in anti-p200 pemphigoid.
Front Immunol
February 2023
Department of Laboratory Medicine, Chronic Disease Research Center, Medical College, Dalian University, Dalian, China.
Article Synopsis
- Anti-p200 pemphigoid is a rare autoimmune skin disease first described in 1996, characterized by skin lesions and potential mucosal involvement, though the mechanisms of mucosal lesions are not well understood.* -
- A review of 32 studies identified 52 patients with mucosal lesions, revealing that 75% had oral lesions, 26.9% genital lesions, and 11.54% ocular lesions, with some patients also having other autoimmune diseases.* -
- The findings suggest that anti-p200 autoantibodies may play a unique role in causing mucosal lesions compared to other related autoimmune diseases, highlighting a distinct pattern, but further research is needed to clarify these mechanisms.*
Anti-Laminin 332-Type Mucous Membrane Pemphigoid.
Biomolecules
October 2022
Department of Laboratory Medicine, Chronic Disease Research Center, Medical College, Dalian University, Dalian 116622, China.
Anti-laminin (LM) 332-type mucous membrane pemphigoid (MMP) is a rare autoimmune bullous disease and was originally discovered as anti-epiligrin cicatricial pemphigoid. Anti-LM332-type MMP has clinical manifestations similar to those of other types of MMP and can only be distinguished through the detection of circulating autoantibodies against LM332. Our group and others have established a number of immunological methods with varying sensitivity and specificity for detection of anti-LM332 autoantibodies; however, none of the established methods has been widely used for clinical diagnosis.
View Article and Find Full Text PDFThe Second Study of Clinical and Immunological Findings in Anti-laminin 332-Type Mucous Membrane Pemphigoid Examined at Kurume University-Diagnosis Criteria Suggested by Summary of 133 Cases.
Front Immunol
February 2022
Department of Dermatology, Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology, Kurume, Japan.
Background: Recently, we published an article retrospectively summarizing the results in 55 anti-laminin 332 (LM332)-type mucous membrane pemphigoid (MMP) cases examined at Kurume University, which were diagnosed by strict inclusion criteria, including positive reactivity in direct immunofluorescence and absence of antibodies to non-LM332 autoantigens. However, indirect immunofluorescence using 1M-NaCl-split normal human skin (ssIIF) is also valuable for diagnosis of anti-LM332-type MMP.
Methods: In this second study, we selected 133 anti-LM332-type MMP cases, which were diagnosed by our different inclusion criteria: (i) immunoglobulin G (IgG) deposition to basement membrane zone (BMZ) by direct immunofluorescence or IgG reactivity with dermal side of split skin by ssIIF, (ii) positivity for at least one of the three subunits of LM332 by immunoblotting of purified human LM332, and (iii) the presence of mucosal lesions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!